Tirzepatide in Canada: Research-Grade, and How It Differs From the Pharmacy Product

Tirzepatide is a synthetic 39-residue peptide with a C20 fatty diacid moiety, engineered as a single molecule that agonizes both the GIP and the GLP-1 receptor. The characterization paper by Coskun et al. (2018) describes the design rationale and the receptor pharmacology, including the deliberately imbalanced potency profile that favours GIP.[3]

The backbone incorporates non-natural residues, notably α-aminoisobutyric acid, to resist DPP-4 cleavage, and the lipidation drives albumin binding and the once-weekly interval. Neither modification is optional decoration: they are what make the molecule behave the way the trials describe.

Research Material

The approved product is manufactured under GMP, released against a pharmacopoeial specification, supplied in a device with a regulated label, and dispensed against a prescription. A research-grade vial shares the molecular target and none of that apparatus. It is manufactured to a supplier specification, released against whatever testing the supplier chooses to do, and labelled for laboratory use.

That is not a criticism of research-grade material; it is a description of what it is. An independent batch certificate is the only thing standing in for the regulatory machinery, which is why the certificate deserves more attention here than in almost any other purchase decision.

Around 4813 Da, 39 residues, lipidated, with non-natural amino acids in the chain. The synthesis is demanding and the characteristic failure modes are deletion and truncation sequences, which a purity assay records as impurity but does not identify. Mass-spectrometry identity confirmation is what turns a purity number into a statement about the right molecule.

Amino Acid Sequence

Chemical Structure

Tirzepatide has the deepest published trial record of any compound in this category. Stated as trial findings, not as properties of a research vial:

• ·Head to head against semaglutide in type 2 diabetes. Frías et al., New England Journal of Medicine 2021 (SURPASS-2): a 40-week open-label randomised trial reporting greater HbA1c and body-weight reduction across tirzepatide doses than semaglutide 1 mg.[1]
• ·Obesity without diabetes. Jastreboff et al., New England Journal of Medicine 2022 (SURMOUNT-1): a 72-week randomised, double-blind, placebo-controlled trial, with mean weight reduction of roughly 15% to 21% across dose arms against 3% for placebo.[2]
• ·Maintenance after withdrawal. Aronne et al., JAMA 2024 (SURMOUNT-4): a randomised withdrawal design reporting substantial weight regain in participants switched to placebo, which is the cleanest published evidence that the effect is pharmacological rather than durable after discontinuation.[4]
• ·Obstructive sleep apnoea. Malhotra et al., New England Journal of Medicine 2024 (SURMOUNT-OSA): reduction in apnoea-hypopnoea index against placebo in adults with obesity and moderate-to-severe OSA.[5]

All of the above was generated with GMP material, at defined doses, under clinical supervision, in named indications. None of it transfers to a research vial as a claim. Health Canada has authorized tirzepatide products for specific human indications through a specific supply chain; a research-grade vial sits outside that authorization entirely and carries no human-use permission of any kind.

Identity, purity and measured content, in that order of importance. Identity by MS confirms the molecule is tirzepatide rather than a cheaper analogue or an incompletely lipidated variant. HPLC purity quantifies synthesis by-products. Measured content confirms the vial holds what the label says, which is the check a purity-only certificate structurally cannot perform.

Every Eppix tirzepatide lot is tested by Janoshik Analytical, published before sale and verifiable on the laboratory's own database. Multiple strengths are stocked, and the buttons under the certificate switch between them.

Published Certificate

Select strength

10mg15mg30mg60mg

Batch

TIRZ-CA-26G-10

Purity (HPLC)

99.634%

Measured content

11.42 mglabelled 10 mg

Laboratory

Janoshik

Verify on the lab’s own databaseAll published certificates

Domestic fulfilment is by Canada Post Xpresspost, typically one to two days nationwide, free over $200, with an Interac e-Transfer discount and mix-and-match pricing at 5 and 10 vials.

Direct comparisons are at semaglutide vs tirzepatide and retatrutide vs tirzepatide. The longer literature overview, separate from this sourcing guide, is at tirzepatide: a research literature overview.

Available at Eppix Labs

Buy Tirzepatide Canada | GIP/GLP-1

10mg · 15mg · 30mg · 60mg

Every batch tested by an independent laboratory, with the certificate published before sale.

From $35.00 CADIn stock